Condition: Endometrial Cancer · Sponsor: University of Chicago
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).
This description comes directly from the study's public registry record.
Christina Son, MD · 773-702-6870 · cancerclinicaltrials@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Active Not Recruiting |
| University of Illinois at Chicago (UIC) | Chicago, Illinois, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04683653